🚨BREAKING STUDY: Intranasal Nano-Ivermectin Shrinks Brain Tumors by...
Nicolas Hulscher, MPH@NicHulscher
112 views
Oct 14, 2025
~1 min read
Advertisement
1
🚨BREAKING STUDY: Intranasal Nano-Ivermectin Shrinks Brain Tumors by 70% Without Toxicity
Landmark preclinical study shows intranasal ivermectin nanocapsules safely shrink glioblastoma in animal models at doses lower than the approved human antiparasitic dose 👇
📍Rats with implanted glioblastoma tumors received intranasal nano-ivermectin for 10 days at 60 µg/day — a dose below the approved human antiparasitic level.
📉Tumor volume dropped by ≈70% compared to untreated controls (79 mm³ vs 254–277 mm³).
📉The treatment also reduced necrosis, edema, and vascular proliferation, indicating less invasive and aggressive tumors.
✅No toxicity was observed — normal liver, kidney, blood, and lung histology; body weight unchanged throughout treatment.
Other formulations — free ivermectin and silica-based particles — showed no significant tumor reduction, highlighting key role of nanocapsule delivery for brain targeting.
These findings align with ivermectin’s 14 distinct anti-cancer mechanisms summarized by Yuwen et al, encompassing inhibition of oncogenic signaling (YAP1, Wnt–TCF, Akt/mTOR, EGFR/NF-κB, MAPK), mitochondrial and oxidative-stress induction, ion-channel modulation, and suppression of both cancer stem cells and the epithelial–mesenchymal transition (EMT).
Clinical translation in humans is urgently needed.
Landmark preclinical study shows intranasal ivermectin nanocapsules safely shrink glioblastoma in animal models at doses lower than the approved human antiparasitic dose 👇
📍Rats with implanted glioblastoma tumors received intranasal nano-ivermectin for 10 days at 60 µg/day — a dose below the approved human antiparasitic level.
📉Tumor volume dropped by ≈70% compared to untreated controls (79 mm³ vs 254–277 mm³).
📉The treatment also reduced necrosis, edema, and vascular proliferation, indicating less invasive and aggressive tumors.
✅No toxicity was observed — normal liver, kidney, blood, and lung histology; body weight unchanged throughout treatment.
Other formulations — free ivermectin and silica-based particles — showed no significant tumor reduction, highlighting key role of nanocapsule delivery for brain targeting.
These findings align with ivermectin’s 14 distinct anti-cancer mechanisms summarized by Yuwen et al, encompassing inhibition of oncogenic signaling (YAP1, Wnt–TCF, Akt/mTOR, EGFR/NF-κB, MAPK), mitochondrial and oxidative-stress induction, ion-channel modulation, and suppression of both cancer stem cells and the epithelial–mesenchymal transition (EMT).
Clinical translation in humans is urgently needed.
Nicolas Hulscher, MPH@NicHulscher
🚨 STUDY – Ivermectin Shows Striking Anticancer Potential and Remarkable Safety
Largest review of ivermectin and cancer to date finds 14 distinct anticancer mechanisms — and no safety concerns ⬇️
✅ Signs of remission & tumor stability
✅ 36 cancer patients – NO serious adverse events
✅ Key mechanisms: YAP1 & Wnt/TCF blockade, Akt/mTOR suppression, cancer stem cell inhibition, ROS induction & mitochondrial dysfunction in cancer cells, EMT inhibition
Clinical trials are urgently needed to confirm these promising signals and explore its full therapeutic potential.
Largest review of ivermectin and cancer to date finds 14 distinct anticancer mechanisms — and no safety concerns ⬇️
✅ Signs of remission & tumor stability
✅ 36 cancer patients – NO serious adverse events
✅ Key mechanisms: YAP1 & Wnt/TCF blockade, Akt/mTOR suppression, cancer stem cell inhibition, ROS induction & mitochondrial dysfunction in cancer cells, EMT inhibition
Clinical trials are urgently needed to confirm these promising signals and explore its full therapeutic potential.
2
By hitting multiple hallmarks of cancer simultaneously — proliferation, metabolism, invasion, and survival — ivermectin appears to function as a multi-targeted anti-tumor agent. These converging effects explain the 70% tumor-volume reduction. thefocalpoints.com/p/new-study-in…
